Facilitators and barriers of infectious diseases surveillance activities: lessons from the Global Polio Eradication Initiative - a mixed-methods study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
12 05 2022
Historique:
entrez: 13 5 2022
pubmed: 14 5 2022
medline: 18 5 2022
Statut: epublish

Résumé

To document lessons from the Global Polio Eradication Initiative (GPEI) by determining factors associated with successful surveillance programme globally as well as at national and subnational levels. The process of conducting surveillance has been previously recognised in the literature as important for the success of polio surveillance activities. A cross-sectional survey with closed and open-ended questions. Survey of persons involved in the implementation of surveillance activities under the GPEI at the global level and in seven low-income and middle-income countries. Individuals (n=802) with ≥12 months of experience implementing surveillance objective of the GPEI between 1988 and 2019. Quantitative and qualitative analyses were conducted. Logistic regression analyses were used to assess factors associated with implementation process as a factor for successful surveillance programme. Horizontal analysis was used to analyse qualitative free-text responses on facilitators and barriers identified for conducting surveillance activities successfully. Overall, participants who reported challenges relating to GPEI programme characteristics had 50% lower odds of reporting implementation process as a factor for successful surveillance (adjusted OR (AOR): 0.50, 95% CI: 0.29 to 0.85). Challenges were mainly perceptions of external intervention source (ie, surveillance perceived as 'foreign' to local communities) and the complexity of surveillance processes (ie, surveillance required several intricate steps). Those who reported organisational challenges were almost two times more likely to report implementation process as a factor for successful surveillance (AOR: 1.89, 95% CI: 1.07 to 3.31) overall, and over threefolds (AOR: 3.32, 95% CI: 1.14 to 9.66) at the national level. Programme characteristics may have impeded the process of conducting surveillance under the GPEI, while organisational characteristics may have facilitated the process. Future surveillance programmes should be designed with inputs from local communities and frontline implementers.

Identifiants

pubmed: 35551082
pii: bmjopen-2022-060885
doi: 10.1136/bmjopen-2022-060885
pmc: PMC9109099
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e060885

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

J Infect Dis. 2014 Nov 1;210 Suppl 1:S540-6
pubmed: 25316878
J Infect Dis. 2017 Jul 1;216(suppl_1):S250-S259
pubmed: 28838187
Wkly Epidemiol Rec. 2013 Jan 4;88(1):1-16
pubmed: 23311010
J Infect Public Health. 2020 Nov;13(11):1630-1638
pubmed: 32855090
Int Health. 2017 May 1;9(3):156-163
pubmed: 28582560
BMC Public Health. 2014 Jul 05;14:687
pubmed: 24996415
BMC Infect Dis. 2016 Oct 27;16(1):611
pubmed: 27784275
J Infect Dis. 2016 May 1;213 Suppl 3:S136-9
pubmed: 26655842
BMC Public Health. 2018 Jul 13;18(1):879
pubmed: 30005613
Nat Rev Immunol. 2021 Dec;21(12):823-828
pubmed: 34697501
Implement Sci. 2020 Aug 28;15(1):69
pubmed: 32859225
Euro Surveill. 2018 Nov;23(47):
pubmed: 30482263
Infect Dis Poverty. 2016 Oct 5;5(1):94
pubmed: 27716398
BMC Public Health. 2020 Aug 12;20(Suppl 2):1197
pubmed: 32787958
BMC Public Health. 2020 Aug 12;20(Suppl 2):1176
pubmed: 32787949
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
MMWR Morb Mortal Wkly Rep. 2019 May 24;68(20):458-462
pubmed: 31120868
J Infect Dis. 2014 Nov 1;210 Suppl 1:S294-303
pubmed: 25316848
Obesity (Silver Spring). 2019 Jan;27(1):11
pubmed: 30569643
Eur Respir J. 2008 Dec;32(6):1616-24
pubmed: 18684850
Am J Community Psychol. 2012 Dec;50(3-4):462-80
pubmed: 22644083

Auteurs

Ikponmwosa Osaghae (I)

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Department of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas Health Science Center at Houston, Houston, Texas, USA.

Priyanka Agrawal (P)

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Adetoun Olateju (A)

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Olakunle Alonge (O)

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA oalonge1@jhu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH